GM-6 is under clinical development by Genervon Biopharmaceuticals and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GM-6’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GM-6 overview
GM-6 is under development for the treatment of amyotrophic lateral sclerosis, acute middle cerebral artery ischemic stroke and Parkinson's disease. The drug candidate is administered through intravenous bolus or intravenously as a solution. GM6 is a peptide-based drug and analog of motoneuronotrophic factor (MNTF). GM6 is an endogenous human embryonic stage neural regulatory and signaling peptide that targets apoptosis regulator BAX, free radicals, insulin receptors IGF1,IGF2, Akt and phosphatidylinositol (3,4,5)-trisphosphate. The drug candidate is developed based on the in-silico analysis platform. It was also under development for Huntington disease, Alzheimer's disease and multiple sclerosis.
Genervon Biopharmaceuticals overview
Genervon Biopharmaceuticals (Genervon) operates as a clinical stage biopharmaceutical company that offers research services. The company discovers and develops new classes of novel master regulators bio-drugs. Its products are used to treat various disorders and diseases in nervous system and vascular system. The company’s lead product GM602, under Phase 2 study, is a drug intended for the treatment of ischemic stroke. Its other pipeline products GM604 and GM608, currently under Phase 2 study, are endogenous human embryonic stage neural regulatory and signaling peptides which are intended for the treatment of amyotrophic lateral disease and Parkinson’s disease respectively. GM6, under Phase 2 clinical development, is a peptide that helps detection and self-correction of central nervous system and neurodegenerative-related pathophysiology. Genervon is headquartered in Pasadena, California, the US.
For a complete picture of GM-6’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - GM-6 in Acute Ischemic Stroke
Premium Insights
The gold standard of business intelligence.
